DOI: https://doi.org/10.22141/2224-1485.2.34.2014.82712

Do We Need Arguments Concerning What is Better, Sartans or ACE Inhibitors? (Part 1)

A.D. Radchenko

Abstract


This article is the first part of the review of the literature data on the mechanism of action and efficacy of angiotensin receptor blockers II (ARBs) in reducing blood pressure and preventing end-organ damage. A comparison with the action of angiotensin-converting enzyme (ACE) inhibitors is being carried out. The authors concluded that the significant difference, that would have clinical significance between ARBs and ACE inhibitors, hasn’t been found.

Keywords


inhibitors of angiotensin-converting enzyme; sartans; efficiency; safety

References


Настанова та клінічний протокол надання медичної допомоги «Артеріальна гіпертензія». Наказ МОЗ України № 384 від 24.05.2012. — Київ, 2012. — 107 с.

2013 ESH/ESC Guidelines for the management of arterial hypertension TheTask Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. — 2013. — Vol. 31. — P. 1281-1357.

Akishita M., Horiuchi M., Yamada H. et al. Inflammation influences vascular remodeling through AT2 expression and signaling // Physiol Genom. — 2000. — Vol. 2. — P. 13-20.

Akishita M., Iwai M., Wu L. et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodelling after aortic banding in mice // Circulation. — 2000. — Vol. 102. — P. 1684-1689.

Alfakih K., Lawrance R.A., Maqbool A. et al. The clinical significance of a common, functional, X-linked angiotensin II type 2-receptor gene polymorphism (–1332 G/A) in a cohort of 509 families with premature coronary artery disease // Eur. Heart J. — 2005. — Vol. 26. — P. 584-589.

Benndorf R., Boger R.H., Ergun S. et al. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells // Circ. Res. — 2003. — Vol. 93. — P. 438-447.

Benneti M., Macdonald K., Chan S. et al. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques // Cir. Res. — 1998. — Vol. 82. — P. 704-712.

Boutouyrie P., Beaussier H., Achouba A., Laurent S. for the EXPLOR trialist. Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure // J. Hypertens. — 2014. — Vol. 32. — P.108-114.

Brenner B., Cooper M., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. — 2001. — Vol. 345. — P. 861-869.

Calvo C., Termida I., Ayala D.E. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension // J. Hypertens. — 2004. — Vol. 22. — P. 837-846.

Cao Z., Dean R., Wu L. et al. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy // Hypertension. — 1999. — Vol. 34. — P. 408-414.

Connolly S., Yusuf S., Swedberg K. et al. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals // J. Hypertension. — 2011. — Vol. 29 (4). — P. 623-635.

D’Amore A., Black M.J., Thomas W.G. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy // Hypertension. — 2005. — Vol. 46. — P. 1347-1354.

Dai W., Funk A., Herdegen T. et al. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats // Stroke. — 1999. — Vol. 30. — P. 2391-2399.

Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

Dalby A., McMurray J. VALIANT trial results support use of valsartan in acute myocardial infarction // Cardiovasc Journal of South Africa. — 2003. — e-publication 5 December 2 — P. 1-3 (www.cvjsa.co.za).

de Gasparo M., Whitebread S. Binding of valsartan to mammalian angiotensin AT1 receptors // Regul. Pept. — 1995. — Vol. 59. — P. 303-311.

Demers C., McMurray J.J., Swedberg K. et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure // JAMA. — 2005. —Vol. 294. — P. 1794-1798.

Destro M., Scabrosetti R., Vanasia A., Mugellini A. Comparative effi cacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring // Adv. Ther. — 2005. — Vol. 22, № 1. — P. 32-43.

Diap Q., Li J., Schiffrin E. In vivo study of AT1 and AT2 angiotensin receptors in apoptosis in rat blood vessels // Hypertension. — 1999. — Vol. 34. — P. 617-624.

Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan // Lancet. — 2002. — Vol. 360. — P. 752-760.

Edwards R.M., Aiyar N., Ohlstein E.H. et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566 // J. Pharmacol. Exp. Ther. — 1992. — Vol. 260. — P. 175-181.

Everett B.M., Glynn R.J., Danielson E. et al. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial // Clin. Ther. — 2008. — Vol. 30. — P. 661-672.

Fabia M.J., Abdilla N., Oltra R., Fernandez C., Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring // J. Hypertens. — 2007. — Vol. 25. — P. 1327-1336.

Fagard R., Celis H., Thijs L., Wouters S. Regression of Left Ventricular Mass by Antihypertensive Treatment A Meta-Analysis of Randomized Comparative Studies // Hypertension. — 2009. — Vol. 54. — P. 1084-1091.

Fitchett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion // Vascular Health and Risk Management. — 2009. — Vol. 5. — P. 21-29.

Fossum E., Olsen M., Höieggen A. et al. Long-Term Effects of a Losartan-Compared With an Atenolol-Based Treatment Regimen on Carotid Artery Plaque Development in Hypertensive Patients With Left Ventricular Hypertrophy: ICARUS, a LIFE Substudy // J. Clin. Hypertens. — 2006. — Vol. 8. — P. 169-173.

Fournier A., Achard J., Boutitie F. et al. Is the angiotensin II type 2 receptor cerebroprotective? // Curr. Hypertens. Rep. — 2004. — Vol. 6. — P. 182-189.

Fried L., Emanuele N., M.D., Zhang J. et al. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy //

N. Engl. J. Med. — 2013. — Vol. 369. — P. 1892-1903.

Galliant S., Busche S., Raizada M. et al. The angiotensin II type 2 receptor: an enigma with multiple variations // Am. J. Physiol. Endocrinol. Metab. — 2000. — Vol. 278. —P. 357-374.

Girerd X., Mourad J., Vaisse B. et al. Estimation of the number of patients treated for hypertension, diabetes or hyperlipidemia in France (Flash Study 2002) // Arch. Mal. Coeur Vaiss. — 2003. — Vol. 96. — P. 750-753.

Granger B.B., Swedberg K., Ekman I. et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial // Lancet. — 2005. — Vol. 366. — P. 2011.

Granger B., McMurray J.J., Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial // Lancet. — 2003. — Vol. 362. — P. 772-776.

Gu Q., Burt V., Dillon C., Yoon S. Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults With Hypertension: The National Health and Nutrition Examination Survey, 2001 to 2010 // Circulation. — 2012. — Vol. 126. — P. 2105-2114.

Hannon O., Laroche P., Vidal J.S. et al. Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients // Ann. Cardiol. Angeiol. (Paris). — 2012. — Vol. 61 (3). — P. 218-23.

Haulica I., Walther Bild W., Serban D. Review: Angiotensin Peptides and their Pleiotropic Actions // J. Renin Angiotensin Aldosterone Syst. — 2005. — Vol. 6. — P. 121-131.

Herbert J.-M., Delisee C., Dol F. et al. Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro // Eur. J. Pharmacol. — 1994. — Vol. 251. — P. 143-50.

Hermida R.C., Ayala D.E., Calvo C. Optimal timing for antihypertensive dosing: focus on valsartan // Ther. Clin. Risk Manag. — 2007. — Vol. 3(1). — P. 119-131.

Hermida R.C., Smolensky M.H. Chronotherapy of hypertension // Curr. Opin. Nephrol. Hypertens. — 2004. — Vol. 13(5). —

P. 501-505.

Hsu T.-W., Jia-Sin Liu, Szu-Chun Hung et al. Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia // JAMA Intern. Med. — 2014. — Vol. 174(3). — P. 347-354.

http://www.kantarhealth.com

http://www.kidney.org/professionals/KDOQI/guidelines_bp/index.htm

Ibsen H., Olsen M.H., Wachtell K. et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: a LIFE study // Hypertension. — 2005. — Vol. 45. —

P. 198-202.

Ichihara S., Senbonmatsu T., Price E. Jr. et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension // Circulation. —

— Vol. 104. — P. 346-351.

Ishimitsu T., Kakeda T., Akashiba A. et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases // Hypertension Research. — 2005. —

Vol. 28. — P. 865-870.

Iwai M., Liu H., Chen R. et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation // Circulation. — 2004. — Vol. 110. — P.843-848

Jöhren O., Dendorfer A., Dominiak P. Review Cardiovascular and renal function of angiotensin II type-2 receptors // Cardiovascular Research. — 2004. — Vol. 62. — P. 460-467.

Jugdutt B., Menon V. Upreg ulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat //

J. Cardiovasc. Pharmacol. Ther. — 2003. — Vol. 8. — P. 217-26.

Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. — 2004. — Vol. 363. — P. 2022-2031.

KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease // Kidney international supplements. — 2012. — Vol. 2. — P. 337-414.

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease // Am. J. Kidney Disease. — 2007. — Vol. 49, Suppl. 2. — P. 1S-179S.

Kim M.P., Zhou M., Wahl L.M. Angiotensin II increases human monocyte matrix etalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture //

J. Leukoc. Biol. — 2005. — Vol. 78. — P. 195-201.

Kohlstedt K., Kellner R., Busse R., Fleming I. Signaling via the angiotensin-converting enzyme results in the phosphorylation of the nonmuscle myosin heavy chain IIA // Mol. Pharmacol. — 2006. —

Vol. 69. — P. 19-26.

Kosch M., Levers A., Lang D. et al. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension // Nephrol. Dial. Transplant. — 2008. — Vol. 23. — P. 2280-2285.

Krikov M., Thone-Reineke C., Müller S., Villringer A., Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats // Journal of Hypertension. — 2008. — Vol. 26. — P. 544-552.

Kunz R., Friedrich C., Wolbers, Mann J.F.E. Meta-analysis: Effect of Monotherapy and Combination Therapy With Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease // Ann. Intern. Med. — 2008. — Vol. 148. — P. 30-48.

Lange S., Wolf B., Schober K. et al. Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart // J. Cardiovasc. Pharmacol. — 2007. — Vol. 49. — P. 46-55.

Lasserson D., Buclin T., Glasziou P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data // Heart. — 2011. —

Vol. 97(21). — P. 1771-1775.

Lévy B., Benessiano I.J., Henrion D. et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure // J. Clin. Invest. — 1996. — Vol. 98. — P. 418-425.

Lévy B. Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease? Implications for Therapeutic Blockade of the Renin-Angiotensin System // Circulation. — 2004. —

Vol. 109. — P. 8-13.

Li J., Culman J., Hortnagi H. et al. Angoitansin AT2 receptor protects against cerebral ischemia-induced neuronal

injury // FASEB J. —2005. — Vol. 19. — P. 617-619.

Lindholm L.H., Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 1004-1010.

Lithell H., Hansson L., Skoog I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial // J. Hypertens. — 2003. —

Vol. 21. — P. 875-886.

MacKinnon M., Shurraw S., Akbari A., Knoll G.A., Jaffey J., Clark H.D. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data // Am. J. Kidney Dis. — 2006. —

Vol. 48. — Р. 8-20.

Maggioni A.P., Latini R., Carson P.E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) // Am. Heart J. — 2005. — Vol. 149. — P. 548-557.

Marott S.C., Nielsen S.F., Benn M., Nordestgaard B.G. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study //

Eur. Heart J. — 2014. — DOI: 10.1093/eurheartj/eht507. Abstrac.

McMurray J., Solomon S., Pieper K. et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT) // J. Am. Coll. Cardiol. — 2006. — Vol. 47. — P. 726 -733.

McMurray J.J., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial // Lancet. — 2003. — Vol. 362. — P. 767-771.

Mehta J.L., Li D.Y., Yang H., Raizada M.K. Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells // J. Cardiovasc. Pharmacol. — 2002. — Vol. 39. — P. 789-794.

Messerli F. Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure Monitoring. A meta-analysis of randomized trial // Am. Coll. Cardiol. — 2011. — Vol. 57. — P. 590-600.

Miura S., Saku K. Do all angiotensin II type 1 receptor blockers have the same beneficial effects? // Br. J. Pharmacol. — 2007. — Vol. 151(7). — P. 912-913.

Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study // Br. Med. J. — 2000. — Vol. 321. — P. 1440-1444.

Möller J., Dahlström U., Götzsche O. et al. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy // Am. Heart J. — 2004. —

Vol. 147. — P. 494-501.

Mörtsell D., Malmqvist K., Held C., Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study // J. Intern. Med. — 2007. — Vol. 261. — P. 472-479.

Nakamura T., Inoue T., Suzuki T. et al. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency // Hypertens. Res. — 2008. — Vol. 31. — P. 841-850.

Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial // Lancet. — 2003. — Vol. 361. — P. 117-124.

Okaka T., Yamamoto H., Okimoto T. et al. Beneficial Effects of Valsartan on Target Lesion Revascularization After Percutaneous Coronary Interventions With Bare Metal Stent // Circulation Journal. —

— Vol. 75. — P. 1641-1648.

Okura T., Watanabe S., Kurata M. et al. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension // Clin. Exp. Hypertens. — 2008. — Vol. 30. — P. 415-422.

Olsen M.H., Wachtell K., Neland K. et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy // Blood Press. — 2005. — 14. — Р. 177-183.

Ong K., Delerme S., Pannier B. et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients // J. Hypertens. — 2011. — Vol. 29. — P. 1034-1132.

Ono H., Minatoguchi S., Watanabe K. et al. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension // Hypertens. Res. — 2008. — Vol. 31. — Р. 271-279.

Otsuka S., Sugano M., Makino N. et al. Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remode-ling in spontaneously hypertensive rats // Hypertension. — 1998. —

Vol. 32. — P. 467-472.

Park D., Yangsoo Jang, Ki-Bae Seung et al. Effect of valsartan on suppression of neointimal hyperplasia after drug-eluting stents and on regression of native plaque volume: the VAL-SUPPRESS randomized controlled trail // JACC. — 2011. — Vol. 57. — E. 1909.

Park M., Chi-yuan Hsu. An ACE in the Hole for Patients With Advanced Chronic Kidney Disease? // JAMA Intern. Med. — 2014. — Vol. 174(3). — P. 355-356.

Parving H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N. Engl. J. Med. — 2001. — Vol. 345. — P. 870-878.

Peters S., Gotting B., Trummel M. et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial // J. Invasive Cardiol. — 2001. — Vol. 13. — Р. 93-97.

Peters S., Trummel M., Meyners W. et al. Valsartan versus ACE inhibition after bare metal stent implantation—results of the VALVACE trial // Int. J. Cardiol. — 2005. — Vol. 98. — Р. 331-335

Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both // N. Engl. J. Med. — 2003. — Vol. 349. — P. 1893-1906.

Pfeffer M.A., Swedberg K., Granger C.B. еt al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme // Lancet. — 2003. — Vol. 362. — P. 759-766.

Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II // Lancet. — 2000. — Vol. 355. — P. 1582-1587.

Pitt B., Segal R., Martinez F.A. et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) // Lancet. — 1997. — Vol. 349. — P. 747-752.

Rayner B. Comments. Telmisartan shown to reduce cardiovascular death, myocardial infarction and stroke in ACE-intolerant high-risk patients // Cardiovascular Journal of South Africa. — 2008, advance publication 10 September. — P. 1.

Robles N., Romero B., Fernandez-Carbonero E. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison // Journal of Renin-Angiotensin-Aldosterone System. — 2009. — Vol. 10. — P. 195.

Schrader J., Luders S., Kulschewski A. et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES) // Stroke. — 2005. — Vol. 36. — P. 1218-1226.

Senbonmatsu T., Ichihara S., Price E. Jr, Gaffney F.A., Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload // J. Clin. Invest. — 2000. — Vol.106. — P. R25-R29.

Sipahi I., Debanne S.M., Rowland D.Y., Simon D.I., Fang J.C. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials // Lancet Oncol. — 2010. — Vol. 11(7). — P. 627-636.

Smolensky M., Hermida R.C., Ayala D.E. et al. Administration-time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension // Blood Press Monit. — 2010. — Vol. 15. — P. 173-180.

Strauss M., Lonn E., Verma S. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists’ Collaboration // European Heart Journal. — 2005. — Vol. 26. — P. 2351-2353.

Strauss M., Hall A. Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox // Circulation. — 2006. —Vol. 114. — P. 838-854.

Strippoli G.F., Craig M., Deeks J.J., Schena F.P., Craig J.C. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review // BMJ. — 2004. — Vol. 9, 329. — P. 828.

The ACTIVE I Investigators Irbesartan in Patients with Atrial Fibrillation // N. Engl. J. Med. — 2011. — Vol. 364. — P. 928-938.

The Investigators. Valsartan for Prevention of Recurrent Atrial Fibrillation // N. Engl. J. Med. — 2009. — Vol. 360. — P. 1606-1617.

The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events // New Engl. J. Med. — 2008. — Vol. 358. — P. 1547-59.

The Task force members. Guidelines in diabetes, prediabetes and cardiovascular disease: full text // Eur. Heart J. — doi:10.1093/eurheartj/ehl261

Thone-Reineke C., Steckelings U.M., Unger T. Angiotensin receptor blockers and cerebral protection in stroke // J. Hypertens. — 2006. — Vol. 24. — P. 115S-121S.

Unger T. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications // J. Renin Angiotensin Aldosterone Syst. — 2001. — Vol. 2. — P. S4-7.

Unger T., Stoppelhaar M. Rationale for double renine-angiotensin-aldosterone system blockade // Am. J. Cardiol. — 2007. — Vol. 100. — P. 25-31.

Vacanti L. Could angiotensin receptor blockers and activation of At2 induce plaque rupture, rather than repair? // BMJ. — 2004. — rapid Response (23 Dec. 2004).

Van de Wall R., Veldhuisen D., van Gilst W., Voors A. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? // European Heart Journal. — 2005. — Vol. 26. —

P. 2361-2367.

Viberti G. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure — Independent Effect. Wheeldon and for the Microalbuminuria Reduction With VALsartan (MARVAL) Study Investigators // Circulation. — 2002. — Vol. 106. — P. 672-678.

Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention For End point reduction in hypertension (LIFE) study // J. Am. Coll. Cardiol. — 2005. — Vol. 45(5). — P. 712-719.

Warnecke C., Mugrauer P., Surder D. et al. Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing // Am. J. Physiol. Regul. Integr. Comp. Physiol. — 2005. — Vol. 289. — P. 1729-1735.

Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical values in the VALUE trial // Lancet. — 2004. — Vol. 363. — P. 2047-2049.

Wolf G. The road not taken: role of angiotensin II type 2 receptor in pathophysiology // Nephrol. Dial. Transplant. — 2002. — Vol. 17. — P. 195-198.

www.comitehta.org

Yan X., Price R.L., Nakayama M. et al. Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice // Am. J. Physiol. Heart Circ. Physiol. — 2003. — Vol. 285. — P. 2179-2187.

Yang X., Liu Y., Mehta D. et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice // Circ. Res. — 2001. — Vol. 88. — P. 1072-1079.

Zannad F., Matzinger A., Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists // Am. J. Hypertens. — 1996. — Vol. 9(7). — P. 633-643.




Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта